Genmab's market cap is currently $17.49B. The company's EPS TTM is $0.542; its P/E ratio is 14.00; Genmab is scheduled to report earnings on August 7, 2025, and the estimated EPS forecast is $0.45. See an overview of income statement, balance sheet, and cash flow financials.
